We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD
Pasi Antero Jänne, MD, PhD
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Charu Aggarwal, MD, MPH
Alexander Drilon, MD
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Intracranial Activity of ROS1 TKIs
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Mamta Parikh, MD, MS
Daniel P. Petrylak, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education